DAFTAR PUSTAKA

Adeghate E, 2008, Visfatin: Structure, Function and Relation to Diabetes Mellitus and Other Dysfunctions, *Current Medicinal Chemistry* Vol.15 No.18, p.1851-1862

Al Khalidy NTT, AL-Samarraie AKY, Rajeb TMA, 2017, Visfatin Level and its Relation with Obesity and Insulin Resistance In Iraqi Type 2 Diabetes Melitus Patients, *Iraqi Journal of Community Medicine*, Vol. 30, p. 24-28

Bekinalkar SAR, Raghavendra B, Goud TG, Vasantha SC, 2015, A study of prevalence of type 2 diabetes mellitus among urban adults of Ballari, India. *International Journal of Community Medicine and Public Health* Nov;2(4), p.660-665.

Carbone F, Liberale L, Bonaventura A, Vecchi`e A, Casula M, Cea M *et al.*, 2017, Regulation and Function of Extracellular Nicotinamide Phosphoribosyltransferase/Visfatin, comprehensive physiology, *American Physiological Society*, p. 603-621

Chang YH, Chang DM, Lin KC, Shin SJ, Lee YJ, 2011, Diabetes/Metabolism Research and Reviews, *Diabetes Metab Res Rev* (27), p.515–527. DOI: 10.1002/dmrr.1201

Chen CC, Wu MT, Li CI, Liu CS, Lin WY, Lai MM *et al.*, 2007, The relationship between visfatin levels and anthropometric and metabolic parameters: association with cholesterol levels in women, *Metabolism Clinical and Experimental* 56, p.1216-1220

Chen M, Chung F, Chang D, Tsai J, Huang H, Shan S *et al.*, 2006, Elevated plasma level of visfatin/Pre-B Cell colony-Enhancing Factor in patients with type 2 Diabetes Melitus, *J Clin Endocrinol Metab.*; 91, p.295-99.

Cobas. 2017. LDLC3 LDL-Cholesterol Gen 3 Package Insert Instruction 201706. Roche Diagnostics GmbH, Mannheim.

Dahlan MS, 2016. Besar Sampel dalam Penelitian Kedokteran dan Kesehatan Seri 2, Edisi 4, Jakarta: Sagung Seto, p: 1-338.

Einarson TR, Acs A, Ludwig C, Panton UH. 2018. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientifc evidence from across the world in 2007–2017. *Cardiovascular Diabetology* 17:83, p.1-19

Eknithiset R, Samrongthong R, Kumar R, 2018, Factors Associated With Knowledge, Perception, and Practice Toward Self-care among Elderly Patients Suffering from Type 2 Diabetes Mellitus in Rural Thailand, *J Ayub Med Coll Abbottabad* 2018;30(1), p.107-10

Elabscience. 2020. Human VF(Visfatin) ELISA Kit. Elabscience.

El-Mesallamy HO, Kassem DH, El-Demerdash E, Amin AI, 2011, Vaspin and visfatin/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus. *Metabolism*, 60(1), p.63–70.

El-Shafey EM, El-Naggar GF, Al-Bedewy MM, El-Sorogy H, 2012, Is There A Relationship Between Visfatin Level and Type 2 Diabetes Melitus In Obese And Non Obese Patients?, *Journal of Diabetes and Metabolism*, S11:001. doi:10.4172/2155-6156.S11-001

Esteghamati A, Nakhjavani M, Alamdari A, Zandieh A, Elahi S, Khalilzadeh O *et al.*, 2011, Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity. *Diabetes research and clinical practice*, p.154–158.

Estienne A, Ducluzeau PH, Bongrani A, Reverchon M, Rame C, Froment P *et al.*, 2019, Involvement of Novel Adipokines, Chemerin, Visfatin, Resistin and Apelin in Reproductive Functions in Normal and Pathological Conditions in Humans and Animal Models, *International Journal Molecular Sciences* (20) 4431; p.1-45

Feingold KR, 2021, Introduction to Lipids and Lipoproteins in: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK305896/

Georg P, Ludvik B, 2000, Lipids and Diabetes, *Journal of Clinical and Basic Cardiology*; 3 (3), p.159-162.

Gligor R, Zdremtan D, Pilat L, Matei I, Ionescu-Tirgovis C, Crisnic I, 2012, Correlations of Visfatin with the Lipidic Metabolism in Diabetic and Obese Patients, *Proc. Rom. Acad.*, p. 37–43

Gunduz FO, Yildirmak ST, Temizel M, Faki Y, Cakmak M, Durmuscan M et al., 2011, Serum visfatin and fetuin-a levels and glycemic control in patients with obese type 2 diabetes mellitus. *Diabetes Metabolism Journal*, p.523-528

Hajianfar H, Bahonar A, Entezari MH, Askari G, Yazdani M, 2012, Lipid Profiles and Serum Visfatin Concentrations in Patients with Type II Diabetes in Comparison with Healthy Controls, *International Journal of Preventive Medicine* (3), p.326-31.

Hirano T, 2018, Pathophysiology of Diabetic Dyslipidemia, *Journal Atherosclerosis Thromb*: 25, p.771-782. Dapat diakses melalui doi.org/10.5551/jat.RV17023

Indrawati L, 2017, Pengaruh Kolesterol Total, Merokok, Tekanan Darah, High Density Lipoprotein, Umur terhadap Penyakit Jantung Koroner pada Pasien Diabetes Melitus Tipe 2 di RSUD Budhi Asih Periode Juli 2015-Maret 2016. Jurnal INOHIM, Volume 5 Nomor 2, hal.65-73

Kementerian Kesehatan Republik Indonesia (KEMENKES RI), 2020, *InfoDATIN Tetap Produktif, Cegah, dan Atasi Diabetes Melitus*, Pusat Data dan Informasi Kementerian Kesehatan RI, Jakarta Selatan.

Kementerian Kesehatan Republik Indonesia (KEMENKES RI), 2019, *Laporan NASIONAL RISKESDAS 2018*, Badan Penelitian dan Pengembangan Kesehatan (Badan Litbangkes), Jakarta.

Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J, 2020, Epidemiology of Type 2 Diabetes – Global Burden of Disease and Forecasted Trends, *Journal of Epidemiology and Global Health* Vol. 10(1); March, p. 107–111.

Low Wang CC, Hess CN, Hiatt WR, Goldfine AB, 2016, Clinical Update: Cardiovascular Disease in Diabetes Mellitus Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus-Mechanisms, Management, and Clinical Considerations. *Circulation*;133. p:2459–2502.

Nesto RW, 2008, LDL Cholesterol Lowering in Type 2 Diabetes: What Is the Optimum Approach? *Clinical Diabetes* Volume 26, Number 1. p.8-13

Perkumpulan Endokrinologi Indonesia (PERKENI), 2019, *Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 Dewasa di Indonesia 2019*, PB PERKENI, Jakarta, p.1-132

Perkumpulan Endokrinologi Indonesia (PERKENI), 2021, *Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 Dewasa di Indonesia 2021*, PB PERKENI, Jakarta, p.1-104

Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI), 2017, Panduan Tata Laksana Dislipidemia 2017, PERKI, Jakarta, p.1-80

Remaley AT, Dayspring TD, Warnick GR, 2018, Lipid, Lipoprotein, Apolipoprotein, and Other Cardiovascular Risk Factors in *Tietz Textbook of Clinical Chemistry and Molecular Diagnostics*, 6th Ed. Editor N. Rifai, AR Horvath dan CT Wittwer, Missouri: Elsevier, p.539-603

Rodriguez-Araujoa G, Nakagamic H, 2018, Pathophysiology of cardiovascular disease in diabetes mellitus, *Cardiovascular Endocrinology & Metabolism*, p.4–9

Romacho T, Sanchez-Ferrer CF, Peiro C, 2013, Review Article Visfatin/Nampt: An Adipokine with Cardiovascular Impact, *Hindawi Publishing Corporation Mediators of Inflammation*, p.1-15

Sommer G, Garten A, Petzold S, Beck-Sickinger AG, Bluher M, Stumvoll M *et al.*, 2008, Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel adipokine, *Clinical Science* 115, p.13-23

Sonoli SS, Shivprasad S, Prasad CVB, Patil AB, Desai PB, Somannavar MS, 2011, Visfatin – a review, *European Review for Medical and Pharmacological Sciences*; 15, p.9-14.

Tahir NT, AL-Samarraie AK, Ali Rajeb TM, 2017, Visfatin Level and its Relation with Obesity and Insulin Resistance In Iraqi Type 2 Diabetes Melitus Patients, *Iraqi J. Comm. Med.*, p.24-28

Timon IM, Collantes CS, Galindo AS, Gomez FJ. 2014. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? *World Journal of Diabetes* August 15; 5(4), p. 444-470

Tsiotra PC, Tsigos C, Yfanti C, Anastasiou E, Vikentiou M, Psarra K *et al.*, 2007, Visfatin, TNF-α and IL-6 mRNA Expression is Increased in Mononuclear Cells from Type 2 Diabetic Women, *Horm Metab Res*, p.758-763

Uslu S, Kebapci N, Kara M, Bal C, 2012, Relationship between adipocytokines and cardiovascularrisk factors in patients with type 2 diabetes melitus, *Experimental and Therapeutic Medicine (*4), p.113-120.

World Health Organisation (WHO), 2016, "Global Report on Diabetes," Working Papers id:10553, eSocialSciences.

Wondmkun YT, 2020, Obesity, Insulin Resistance, and Type 2 Diabetes: Associations and Therapeutic Implications, *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*:13, p.3611–3616

Zheng LY, Xu X, Wan RH, Xia S, Lu J, Huang Q, 2019, Association between serum visfatin levels and atherosclerotic plaque in patients with type 2 diabetes, *Diabetology Metabolic Syndrome* 11:60, p.1-7.